J
Joel Picus
Researcher at Washington University in St. Louis
Publications - 223
Citations - 22265
Joel Picus is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 59, co-authored 213 publications receiving 19790 citations. Previous affiliations of Joel Picus include Cleveland Clinic & Medical University of South Carolina.
Papers
More filters
Journal ArticleDOI
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer,Charles G. Drake,Ira Wollner,John D. Powderly,Joel Picus,William H. Sharfman,Elizabeth Stankevich,Alice Pons,Theresa M. Salay,Tracee L. McMiller,Marta M. Gilson,Changyu Wang,Mark J. Selby,Janis M. Taube,Robert A. Anders,Lieping Chen,Alan J. Korman,Drew M. Pardoll,Israel Lowy,Suzanne L. Topalian +19 more
TL;DR: Blocking the PD-1 immune checkpoint with intermittent antibody dosing is well tolerated and associated with evidence of antitumor activity, and tumor cell surface B7-H1 expression appeared to correlate with the likelihood of response to treatment.
Journal ArticleDOI
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher Sweeney,Yu-Hui Chen,Michael A. Carducci,Glenn Liu,David F. Jarrard,Mario A. Eisenberger,Yu-Ning Wong,Noah M. Hahn,Manish Kohli,Matthew M. Cooney,Robert Dreicer,Nicholas J. Vogelzang,Joel Picus,Daniel H. Shevrin,Maha Hussain,Jorge A. Garcia,Robert S. DiPaola +16 more
TL;DR: Six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer resulted in significantly longer overall survival than that with ADT alone.
Journal ArticleDOI
Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
Steven J. Cohen,Cornelis J A Punt,Nicholas Iannotti,B. H. Saidman,Kert D. Sabbath,Nashat Y. Gabrail,Joel Picus,Michael A. Morse,Edith P. Mitchell,M. Craig Miller,Gerald V. Doyle,H. Tissing,Leon W.M.M. Terstappen,Neal J. Meropol +13 more
TL;DR: The number of CTCs before and during treatment is an independent predictor of PFS and OS in patients with metastatic colorectal cancer and Baseline and follow-up CTC levels remained strong predictors of P FS and OS after adjustment for clinically significant factors.
Journal ArticleDOI
Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
Philip W. Kantoff,Susan Halabi,Mark R. Conaway,Joel Picus,Jeffrey J. Kirshner,Vera Hars,Donald L. Trump,Eric P. Winer,Nicholas J. Vogelzang +8 more
TL;DR: M+H generated more frequent responses and a delay in both time to treatment failure and disease progression compared with hydrocortisone alone, and there was an indication that QOL was better with M+H, in particular with respect to pain control.
Journal ArticleDOI
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini,Susan Halabi,Jonathan E. Rosenberg,Walter M. Stadler,Daniel A. Vaena,San San Ou,Laura Archer,James N. Atkins,Joel Picus,Piotr Czaykowski,Janice P. Dutcher,Eric J. Small +11 more
TL;DR: Bvacizumab plus IFN produces a superior PFS and ORR in untreated patients with metastatic RCC as compared with IFN monotherapy, and overall toxicity was greater in the combination therapy arm.